NCT00518206 - Study of NY-ESO-1 ISCOMATRIX® in Patients With Measurable Stage III or IV Melanoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 28, 2003

Primary Completion Date

January 22, 2010

Study Completion Date

January 22, 2010

Conditions

Melanoma

Interventions

BIOLOGICAL

NY-ESO-1 ISCOMATRIX® vaccine

NY-ESO-1 ISCOM vaccine (100 μg of the NY-ESO-1 protein formulated with 120 μg of ISCOM adjuvant) administered as an intramuscular injection every 4 weeks for 3 doses in every cycle.

DRUG

Cyclophosphamide

Cyclophosphamide (300 mg/m\^2) administered as an intravenous injection 1 day prior to each vaccination with NY-ESO-1 ISCOM (100 μg of the NY-ESO-1 protein formulated with 120 μg of ISCOM adjuvant), which was administered as an intramuscular injection every 4 weeks for 3 doses in every cycle.

Trial Locations (2)

3002

Peter MacCallum Cancer Institute, East Melbourne

3084

Austin Health (Ludwig Institute Oncology Unit), Heidelberg